Litcius/Paper detail

Inhibitory effects of Formononetin on CoCrMo particle-induced osteoclast activation and bone loss through downregulating NF-κB and MAPK signaling

Xin Yu, Binkui Yang, Bin Chen, Qi Wu, Zhengrong Ren, Dongsheng Wang, Tao Yuan, Hao Ding, Chao Ding, Yang Liu, Lei Zhang, Zhongyang Sun, Jianning Zhao

2023Cellular Signalling17 citationsDOIOpen Access PDF

Abstract

Wear particle-induced osteoclast over-activation is a major contributor to periprosthetic osteolysis and aseptic loosening, which can cause pathological bone loss and destruction. Hence, inhibiting excessive osteoclast-resorbing activity is an important strategy for preventing periprosthetic osteolysis. Formononetin (FMN) has been shown to have protective effects against osteoporosis, but no previous study has evaluated the effects of FMN on wear particle-induced osteolysis. In this study, we found that FMN alleviated CoCrMo alloy particles (CoPs)-induced bone loss in vivo and inhibited the formation and bone-resorptive function of osteoclasts in vitro. Moreover, we revealed that FMN exerted inhibitory effects on the expression of osteoclast-specific genes via the classical NF-κB and MAPK signaling pathways in vitro. Collectively, FMN is a potential therapeutic agent for the prevention and treatment of periprosthetic osteolysis and other osteolytic bone diseases.

Topics & Concepts

OsteolysisOsteoclastFormononetinNF-κBMAPK/ERK pathwayBone resorptionChemistryCancer researchIn vivoCell biologyIn vitroOsteoporosisSignal transductionMedicineInternal medicineBiochemistryBiologyDentistryBiotechnologyDaidzeinGenisteinOrthopaedic implants and arthroplastyBone Metabolism and DiseasesBone and Joint Diseases
Inhibitory effects of Formononetin on CoCrMo particle-induced osteoclast activation and bone loss through downregulating NF-κB and MAPK signaling | Litcius